Pacira BioSciences announced solid first quarter 2026 financial results with a 5% revenue increase to $177 million, driven by growth across its product portfolio including EXPAREL, ZILRETTA, and iovera°. The company highlighted successful execution of its 5x30 strategy aimed at long-term value creation, with stock up over 30% since its launch. Pacira is urging shareholders to vote for its highly qualified board nominees to prevent activist investor DOMA Perpetual from disrupting its strategic plan, which includes cost cuts and an immediate sale. The company remains confident in its growth trajectory and pipeline advancements with key clinical readouts expected later in 2026.
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
POSCO International, South Korea's largest trading company, is piloting the tokenization of real commercial invoices on the Injective blockchain in partnership with LG CNS. This pilot creates a unified, transferable onchain record for trade receivabl...
Shiba Inu (SHIB) experienced a sharp 15% increase, breaking key resistance levels with strong volume, signaling potential trend reversal if momentum holds. Bitcoin (BTC) stabilized around $64,300, showing signs of healthy accumulation but still faces...
Nearly 3,080 BTC worth about $198 million were withdrawn from Kraken by large holders, signaling long-term accumulation rather than immediate selling. This move, combined with a sharp rise in Bitcoin's Stock-to-Flow Ratio and reduced selling by miner...
